AAPL353.11+21.21 (+6.39%) ▲|ABBV285.72-0.28 (-0.10%) ▼|ABT114.57+5.17 (+4.73%) ▲|ACN265.25+10.69 (+4.20%) ▲|ADBE252.87+6.73 (+2.73%) ▲|AMAT370.29-11.63 (-3.05%) ▼|AMD486.66+2.76 (+0.57%) ▲|AMGN473.30+12.04 (+2.61%) ▲|AMT195.14+7.85 (+4.19%) ▲|AMZN266.71+16.02 (+6.39%) ▲|AVGO326.33-5.80 (-1.75%) ▼|AXP331.89+6.39 (+1.96%) ▲|BA176.92+3.61 (+2.08%) ▲|BAC51.57+1.91 (+3.85%) ▲|BKNG172.39+16.72 (+10.74%) ▲|BLK1,216.59+55.27 (+4.76%) ▲|BMY63.02+1.31 (+2.12%) ▲|BNY149.93+0.62 (+0.41%) ▲|BRK-B572.73+15.66 (+2.81%) ▲|C125.21+2.50 (+2.04%) ▲|CAT583.50-40.44 (-6.48%) ▼|CL99.32+3.70 (+3.87%) ▲|CMCSA24.91+1.24 (+5.22%) ▲|COF203.97-4.75 (-2.27%) ▼|COP137.90-6.50 (-4.50%) ▼|COST1,050.06+30.80 (+3.02%) ▲|CRM228.20+6.00 (+2.70%) ▲|CSCO102.61-0.36 (-0.35%) ▼|CVS81.22-10.19 (-11.15%) ▼|CVX217.92-7.35 (-3.26%) ▼|DE662.93-2.90 (-0.44%) ▼|DHR232.12+2.01 (+0.87%) ▲|DIS119.86+5.68 (+4.97%) ▲|DUK129.64+3.13 (+2.47%) ▲|EMR168.37+1.98 (+1.19%) ▲|FDX322.80+4.78 (+1.50%) ▲|GD363.39-11.11 (-2.97%) ▼|GE323.01+2.34 (+0.73%) ▲|GEV812.57-105.64 (-11.50%) ▼|GILD173.37+5.90 (+3.52%) ▲|GM93.09+4.75 (+5.38%) ▲|GOOG289.52+11.25 (+4.04%) ▲|GOOGL291.28+11.25 (+4.02%) ▲|GS917.09+21.00 (+2.34%) ▲|HD349.60+15.94 (+4.78%) ▲|HON226.45+2.40 (+1.07%) ▲|IBM256.19+6.15 (+2.46%) ▲|INTC57.56-3.00 (-4.95%) ▼|INTU361.98+17.26 (+5.01%) ▲|ISRG482.60+41.85 (+9.50%) ▲|JNJ272.93+6.76 (+2.54%) ▲|JPM349.84+11.86 (+3.51%) ▲|KO96.17+1.37 (+1.44%) ▲|LIN523.87+12.32 (+2.41%) ▲|LLY1,431.00+21.62 (+1.53%) ▲|LMT598.56-40.44 (-6.33%) ▼|LOW227.36+13.98 (+6.55%) ▲|LRCX225.05-5.67 (-2.46%) ▼|MA669.09+21.91 (+3.39%) ▲|MCD276.90+13.86 (+5.27%) ▲|MDLZ67.85+2.73 (+4.19%) ▲|MDT104.45+5.57 (+5.63%) ▲|META629.26+8.23 (+1.33%) ▲|MMM192.08+15.03 (+8.49%) ▲|MO78.42+1.48 (+1.92%) ▲|MRK148.47+3.80 (+2.63%) ▲|MS191.00+4.91 (+2.64%) ▲|MSFT553.68+32.69 (+6.27%) ▲|MU804.52-50.58 (-5.92%) ▼|NEE88.10+3.77 (+4.47%) ▲|NFLX66.07+2.65 (+4.17%) ▲|NKE40.67+2.19 (+5.68%) ▲|NOW109.90+0.74 (+0.68%) ▲|NVDA202.58-4.11 (-1.99%) ▼|ORCL125.60-0.59 (-0.47%) ▼|PEP143.51+6.24 (+4.55%) ▲|PFE30.52+0.52 (+1.73%) ▲|PG167.56+5.50 (+3.39%) ▲|PLTR171.38-4.02 (-2.29%) ▼|PM211.56+3.53 (+1.70%) ▲|QCOM165.57+1.14 (+0.69%) ▲|RTX195.21-8.61 (-4.22%) ▼|SBUX108.67+3.90 (+3.72%) ▲|SCHW92.63+3.35 (+3.75%) ▲|SO92.27-1.48 (-1.58%) ▼|SPG227.15+5.07 (+2.28%) ▲|T22.00+0.61 (+2.83%) ▲|TMO701.50+3.16 (+0.45%) ▲|TMUS160.11+5.70 (+3.69%) ▲|TSLA382.71-15.79 (-3.96%) ▼|TXN308.07-4.42 (-1.41%) ▼|UBER71.43+4.83 (+7.25%) ▲|UNH404.65+0.21 (+0.05%) ▲|UNP305.39+1.96 (+0.64%) ▲|UPS113.61+4.44 (+4.06%) ▲|USB60.50+0.61 (+1.02%) ▲|V432.75+12.33 (+2.93%) ▲|VZ46.41+1.17 (+2.58%) ▲|WFC86.69+1.16 (+1.35%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM170.81-6.66 (-3.75%) ▼|AAPL353.11+21.21 (+6.39%) ▲|ABBV285.72-0.28 (-0.10%) ▼|ABT114.57+5.17 (+4.73%) ▲|ACN265.25+10.69 (+4.20%) ▲|ADBE252.87+6.73 (+2.73%) ▲|AMAT370.29-11.63 (-3.05%) ▼|AMD486.66+2.76 (+0.57%) ▲|AMGN473.30+12.04 (+2.61%) ▲|AMT195.14+7.85 (+4.19%) ▲|AMZN266.71+16.02 (+6.39%) ▲|AVGO326.33-5.80 (-1.75%) ▼|AXP331.89+6.39 (+1.96%) ▲|BA176.92+3.61 (+2.08%) ▲|BAC51.57+1.91 (+3.85%) ▲|BKNG172.39+16.72 (+10.74%) ▲|BLK1,216.59+55.27 (+4.76%) ▲|BMY63.02+1.31 (+2.12%) ▲|BNY149.93+0.62 (+0.41%) ▲|BRK-B572.73+15.66 (+2.81%) ▲|C125.21+2.50 (+2.04%) ▲|CAT583.50-40.44 (-6.48%) ▼|CL99.32+3.70 (+3.87%) ▲|CMCSA24.91+1.24 (+5.22%) ▲|COF203.97-4.75 (-2.27%) ▼|COP137.90-6.50 (-4.50%) ▼|COST1,050.06+30.80 (+3.02%) ▲|CRM228.20+6.00 (+2.70%) ▲|CSCO102.61-0.36 (-0.35%) ▼|CVS81.22-10.19 (-11.15%) ▼|CVX217.92-7.35 (-3.26%) ▼|DE662.93-2.90 (-0.44%) ▼|DHR232.12+2.01 (+0.87%) ▲|DIS119.86+5.68 (+4.97%) ▲|DUK129.64+3.13 (+2.47%) ▲|EMR168.37+1.98 (+1.19%) ▲|FDX322.80+4.78 (+1.50%) ▲|GD363.39-11.11 (-2.97%) ▼|GE323.01+2.34 (+0.73%) ▲|GEV812.57-105.64 (-11.50%) ▼|GILD173.37+5.90 (+3.52%) ▲|GM93.09+4.75 (+5.38%) ▲|GOOG289.52+11.25 (+4.04%) ▲|GOOGL291.28+11.25 (+4.02%) ▲|GS917.09+21.00 (+2.34%) ▲|HD349.60+15.94 (+4.78%) ▲|HON226.45+2.40 (+1.07%) ▲|IBM256.19+6.15 (+2.46%) ▲|INTC57.56-3.00 (-4.95%) ▼|INTU361.98+17.26 (+5.01%) ▲|ISRG482.60+41.85 (+9.50%) ▲|JNJ272.93+6.76 (+2.54%) ▲|JPM349.84+11.86 (+3.51%) ▲|KO96.17+1.37 (+1.44%) ▲|LIN523.87+12.32 (+2.41%) ▲|LLY1,431.00+21.62 (+1.53%) ▲|LMT598.56-40.44 (-6.33%) ▼|LOW227.36+13.98 (+6.55%) ▲|LRCX225.05-5.67 (-2.46%) ▼|MA669.09+21.91 (+3.39%) ▲|MCD276.90+13.86 (+5.27%) ▲|MDLZ67.85+2.73 (+4.19%) ▲|MDT104.45+5.57 (+5.63%) ▲|META629.26+8.23 (+1.33%) ▲|MMM192.08+15.03 (+8.49%) ▲|MO78.42+1.48 (+1.92%) ▲|MRK148.47+3.80 (+2.63%) ▲|MS191.00+4.91 (+2.64%) ▲|MSFT553.68+32.69 (+6.27%) ▲|MU804.52-50.58 (-5.92%) ▼|NEE88.10+3.77 (+4.47%) ▲|NFLX66.07+2.65 (+4.17%) ▲|NKE40.67+2.19 (+5.68%) ▲|NOW109.90+0.74 (+0.68%) ▲|NVDA202.58-4.11 (-1.99%) ▼|ORCL125.60-0.59 (-0.47%) ▼|PEP143.51+6.24 (+4.55%) ▲|PFE30.52+0.52 (+1.73%) ▲|PG167.56+5.50 (+3.39%) ▲|PLTR171.38-4.02 (-2.29%) ▼|PM211.56+3.53 (+1.70%) ▲|QCOM165.57+1.14 (+0.69%) ▲|RTX195.21-8.61 (-4.22%) ▼|SBUX108.67+3.90 (+3.72%) ▲|SCHW92.63+3.35 (+3.75%) ▲|SO92.27-1.48 (-1.58%) ▼|SPG227.15+5.07 (+2.28%) ▲|T22.00+0.61 (+2.83%) ▲|TMO701.50+3.16 (+0.45%) ▲|TMUS160.11+5.70 (+3.69%) ▲|TSLA382.71-15.79 (-3.96%) ▼|TXN308.07-4.42 (-1.41%) ▼|UBER71.43+4.83 (+7.25%) ▲|UNH404.65+0.21 (+0.05%) ▲|UNP305.39+1.96 (+0.64%) ▲|UPS113.61+4.44 (+4.06%) ▲|USB60.50+0.61 (+1.02%) ▲|V432.75+12.33 (+2.93%) ▲|VZ46.41+1.17 (+2.58%) ▲|WFC86.69+1.16 (+1.35%) ▲|WMT130.01+5.15 (+4.12%) ▲|XOM170.81-6.66 (-3.75%) ▼|
19.7 C
New York
Wednesday, November 4, 2026

Tag: company

newsFORsourcecompanycontentinformationreleases1market

Eve Air Mobility Twenty-Year Market Outlook Highlights Growth of Urban Air Mobility Globally

Outlook highlights a $280 billion passenger revenue and 30,000 aircraft opportunities driven by urban population growth, traffic concerns, and a commitment to sustainability. PARIS,...

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients

Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment and dosing of non-ambulatory patients will be immediately paused until additional risk mitigation measures (e.g. immune modulatory treatment) are implemented in the study protocol. Health authorities, investigators and physicians are being informed so that patient care can be quickly adjusted.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025.

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Current Investigation Into Compass Diversified Holdings (NYSE: CODI)

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a shareholder and consumer rights litigation firm, is investigating whether Compass Diversified Holdings (“Compass” or the “Company”) (NYSE: CODI) or certain of its officers and directors issued misleading and false statements and/or failed to disclose information material to investors in violation of federal securities laws.

Ram Brand Launches ‘Never Stop Being American’ Marketing Campaign, New Brand Ethos ‘Nothing Stops Ram’

"Never Stop Being American" marketing campaign takes off across broadcast and Ram brand's social media channelsCampaign celebrates America, its people, pastimes and traditions, formally...

Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025

HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company’s Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1.

Nuclear Air Filtration for HVAC Managers: Why the Nuclear Comeback Demands Next-Gen Filtration Standards

The Big Reveal: What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites. 
The Big Reveal:  What HVAC Managers Must Know About High-Performance Filtration. Camfil Nuclear air filters are used for containment control during dismantling or maintenance work at a nuclear sites.

Sport Clips Haircuts Hosts National Signing Days

Recruiting Top Styling Talent Ready for the Big Leagues GEORGETOWN, Texas, June 14, 2025 /PRNewswire/ -- Styling professionals looking to take their careers to the next...

Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria

11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response

PFMCrypto’s “1-Day Mining Contract” Sales Surge 76% – $1 Million Giveaway Ignites Community Buzz

As PFMCrypto’s AI-driven mining model gains momentum, the platform celebrates a major milestone with a global bonus campaign for new users 
As PFMCrypto’s AI-driven mining model gains momentum, the platform celebrates a major milestone with a global bonus campaign for new users

UPDATE — Ready Capital Corporation Declares Second Quarter 2025 Dividends

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) -- Ready Capital Corporation (NYSE:RC) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.125 per share of common stock and Operating Partnership unit for the quarter ended June 30, 2025. This dividend is payable on July 31, 2025, to shareholders of record as of the close of business on June 30, 2025.

CODI SHAREHOLDERS: Compass Diversified Holdings Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 8 Deadline (NYSE:CODI)

Compass Diversified Holdings investors that lost money are notified to contact BFA Law before July 8, 2025 securities fraud class action deadline.

ELV SHAREHOLDERS: Elevance Health, Inc. Investors are Reminded of the Pending Securities Fraud Class Action – Contact BFA Law by July 11 Deadline (NYSE:ELV)

Elevance Health, Inc. investors that lost money are notified to contact BFA Law before July 11, 2025 securities fraud class action deadline.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IOVA

NEW YORK, June 14, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsCompany

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers